# Acta Pharmacologica Sinica

Contents

Monthly 2024 December; 45 (12)

# Acta Pharmacologica Sinica

Contents

Monthly 2024 December; 45 (12)




**Cover**

**Diagram of the proposed mechanisms by which CEMIP reduces the chemotherapy sensitivity of SCLC cells. CEMIP, an adaptor protein, interacts with SRC and YAP. CEMIP binds to SRC, allowing autophosphorylation of Y416 and activation of SRC, which facilitates the interaction between YAP and activated SRC, resulting in increased phosphorylation of Y357, protein stability, nuclear accumulation and transcriptional activation of YAP, thus reducing the chemotherapeutic sensitivity of SCLC cells. The SRC inhibitor dasatinib and the YAP inhibitor verteporfin display synergistic antitumor effects on SCLC both in vitro and in vivo. See the article in pages 2657–2671.**


**EXECUTIVE EDITOR FOR THIS ISSUE** XU, Jia (Shanghai)

**ACTA PHARMACOLOGICA SINICA** (Monthly)
2024 December; Volume 45 Number 12
(Founded in September, 1980)

**Sponsored by**
Chinese Pharmacological Society
Shanghai Institute of Materia Medica, Chinese Academy of Sciences
**Supervised by**
China Association for Science and Technology
**Editor-in-chief**
DING, Jian
**Edited by**
Editorial Board of Acta Pharmacologica Sinica
294 Tai-yuan Road, Shanghai 200031, China
Http://www.chinaphar.com
E-mail aps@simm.ac.cn
Phn 86-21-5492-2821, 5492-2822; Fax 86-21-5492-2823

**Published jointly by**
Editorial Office of Acta Pharmacologica Sinica
Springer Nature
**Publication date**
5th every month
**Printed by**
Shanghai Shengtong Times Printing Co Ltd
568 Guang-ye Road, Shanghai 201506, China





《中国药理学报》编辑部出版
国内统一连续出版物号
CN 31-1347/R

国内外公开发行
国内邮发代号 4-295
国内每期 200.00 元